How to buy Oxford Immunotec Global stock

Oxford Immunotec Global is a diagnostics & research business based in the US. Oxford Immunotec Global shares (OXFD) are listed on the NASDAQ and all prices are listed in US Dollars. Oxford Immunotec Global employs 273 staff and has a trailing 12-month revenue of around $57.3 million.

Oxford Immunotec Global stock price (NASDAQ: OXFD)

Use our graph to track the performance of OXFD stocks over time.

Oxford Immunotec Global shares at a glance

• Key figures

Information last updated 2021-05-02.

52-week range	$0.00 - $0.00
50-day moving average more info button	$21.94
200-day moving average more info button	$16.48
Wall St. target price	$22.50
PE ratio more info button	11.746
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$5.18

Buy Oxford Immunotec Global stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Oxford Immunotec Global stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Oxford Immunotec Global stock undervalued or overvalued?

Valuing Oxford Immunotec Global stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oxford Immunotec Global's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Oxford Immunotec Global's P/E ratio

Oxford Immunotec Global's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Oxford Immunotec Global shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Oxford Immunotec Global financials

Revenue TTM	$57.3 million
Gross profit TTM	$54.4 million
Return on assets TTM	-4.99%
Return on equity TTM	-8.19%
Profit margin	-30.51%
Book value	$7.37
Market capitalisation more info button	$562.5 million

TTM: trailing 12 months

Oxford Immunotec Global share dividends

We're not expecting Oxford Immunotec Global to pay a dividend over the next 12 months.

Oxford Immunotec Global share price volatility

Over the last 12 months, Oxford Immunotec Global's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oxford Immunotec Global's is 1.3781. This would suggest that Oxford Immunotec Global's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oxford Immunotec Global overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT. TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT. CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions.

Frequently asked questions

What percentage of Oxford Immunotec Global is owned by insiders or institutions?
Currently 1.894% of Oxford Immunotec Global shares are held by insiders and 95.723% by institutions. How many people work for Oxford Immunotec Global?
Latest data suggests 273 work at Oxford Immunotec Global. When does the fiscal year end for Oxford Immunotec Global?
Oxford Immunotec Global's fiscal year ends in December. Where is Oxford Immunotec Global based?
Oxford Immunotec Global's address is: 143 Park Drive, Abingdon, United Kingdom, OX14 4SE What is Oxford Immunotec Global's ISIN number?
Oxford Immunotec Global's international securities identification number is: GB00BGFBB958 What is Oxford Immunotec Global's CUSIP number?
Oxford Immunotec Global's Committee on Uniform Securities Identification Procedures number is: G6855A103